Truist raised the firm’s price target on Insmed (INSM) to $214 from $139 and keeps a Buy rating on the shares. The company’s Q3 results showcased Insmed’s robust commercial execution with two commercial products beating consensus expectations, and the firm expects concerns around market access for Brinsupri to eventually be resolved as physician awareness of this first in disease therapy increases, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INSM:
- Insmed’s Earnings Call: Achievements and Caution
- BofA boosts Insmed price target, says one of the stronger stories in the space
- Insmed price target raised to $215 from $139 at RBC Capital
- Insmed price target raised to $223 from $194 at UBS
- Strong Buy Rating for Insmed Driven by Brinsupri’s Success and Promising Pipeline